Venatorx

Venatorx Pharmaceuticals is discovering and developing novel anti-infectives to treat drug resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead product is an injectable beta-lactamase inhibitor (BLI) with potent and selective activity against both serine- and metallo-beta-lactamases and has recently released positive Phase III clinical data. The company has recently completed distribution agreements on this product for both US and ex-US market. In addition, Venatorx has a broad pipeline of programmes including an orally bioavailable broad-spectrum BLI currently in clinical test, a novel class of penicillin-binding protein inhibitors and novel antiviral agents targeting Hepatitis B.